Transcatheter Aortic Valve Replacement: What's In It for Your Patient?

Transcatheter Aortic Valve Replacement: What's In It for Your Patient? Posted By:
...

Over the last few years more and more development and technology has been devoted to transcatheter aortic valve replacement, or TAVR. This procedure, developed and used for only those with severe aortic stenosis, is done by either a self-expanding or balloon expanding catheter that places the native or replaced valve leaflets against the aortic root walls, creating a new valve structure. The technology is rapidly improving, and the early success was mixed. Concern still remains on the potential for stroke with this procedure. As the device is deployed by either self-expanding or balloon technique, there is the potential for an embolic event or hypoperfusion to occur that can cause a cerebrovascular accident (CVA). Another risk associated with this procedure is the creation of an embolus on the aortic root wall that has potential to dislodge.

The initial data on these new procedures are not consistent, and questions are raised as to the real number of increased CVAs and lesions that result. In addition, recent studies suggest that in patients who undergo these procedures, there may be a small showering effect of emboli that are silent—without symptoms detected—or transient in nature. In some studies, most of these events appear to have resolved after a 3-month post-procedure time frame. To help counter these potential adverse effects, measures are being taken and used where other devices are employed to attempt to capture any emboli or material that may have the potential to cause a stroke.

All in all, the success levels for this procedure are still noteworthy and a consideration for patients who have severe disease and significant quality-of-life issues. PAs and nurse practitioners who have patients with this condition should consider getting a cardiology evaluation so that patients may get the most up-to-date advice on managing this disease.

References
  • Abdel-Wahab M, Mehilli J, Frerker C, et al. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA. 2014;311:1503-1514.
  • Eggebrecht H, Schmermund A, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention. 2012;8:129-138.
  • Ghanem A, Müller A, Nähle CP, et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol. 2010;55:1427-1432.
  • Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation. 2010;121:870-878.
  • Khatri PJ, Webb JG, Rodés-Cabau J, et al. Adverse effects associated with transcatheter aortic valve implantation: a meta-analysis of contemporary studies. Ann Intern Med. 2013;158:35-46.
  • Lansky AJ, Schofer J, Tchetche D, et al. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J. 2015;36:2070-2078.
  • Van Mieghem NM, El Faquir N, Rahhab Z, et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015;8:718-724.

Share

Filed under: Cardiometabolic

Related
Phase III FLOW Trial Results Establishes Semaglutide’s Role in Treating T2D and CKD

Phase III FLOW Trial Results Establishes Semagluti ...

The highly anticipated results of the FLOW (Evaluate Renal Function with Semaglutide Once Weekly) tr ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
The Gift of Time and Key Connection Between Diabetes Mellitus and Autoimmune Disorders

The Gift of Time and Key Connection Between Diabet ...

Are you aware that approximately 64,000 Americans are diagnosed with type 1 diabetes (T1D) each year ...

Filed under: Cardiometabolic


Continue Reading
The Importance of Shared Decision-making in Obesity

The Importance of Shared Decision-making in Obesit ...

Many areas of healthcare are starting to talk about the importance of shared decision-making (SDM), ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Addressing ASCVD Risk in HIV: An Update to the DHHS HIV Guidelines

Addressing ASCVD Risk in HIV: An Update to the DHH ...

The incidence of atherosclerotic cardiovascular disease (ASCVD) is estimated to be twice as high in ...

Filed under: Infectious Diseases, Preventive Medicine, Public Health, Cardiometabolic, NPs & PAs


Continue Reading
Understanding the Multifactorial Etiology of Obesity and the Metabolic Adaptations to Weight Loss

Understanding the Multifactorial Etiology of Obesi ...

Obesity Causes Overeating, Not the Other Way AroundOne of my favorite quotes from Dr Lee Kaplan is, ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading